News
The day at a glance · 3 min read
Mood · Risk-On
+72
Sentiment, −100 to +100
Foundayo MACE-4 Risk Reduction
16%vs insulin glargine
Foundayo MACE-3 Risk Reduction
23%vs insulin glargine
Breyanzi Run Rate
$1B+achieved in 2025
Key driverEli Lilly's positive cardiovascular safety data for obesity pill Foundayo and accelerating M&A activity with Organon takeover bid
Daily briefHealthcare· Money365.Market AI ·

Lilly's Obesity Pill Aces Cardio Safety; Organon M&A Heats Up

Eli Lilly reports positive ACHIEVE-4 data for Foundayo while Sun Pharma eyes $10-12B Organon buyout; BMY's Breyanzi crosses $1B threshold.

Big Pharma & Biotech

Bullish

Moderna Share Price

$54.26+2.69%
LLYBMYMRNA
Eli Lilly ($LLY) reported positive results from ACHIEVE-4, the longest Phase 3 study of its newly approved obesity pill Foundayo (orforglipron), demonstrating cardiovascular safety and efficacy in adults with type 2 diabetes and obesity. The trial met its primary objective of non-inferiority versus insulin glargine, showing a 16% lower risk of MACE-4 events and a 23% lower risk of MACE-3 events. The data reaffirmed Foundayo's cardiovascular and overall safety profile along with consistent improvements across key measures of cardiometabolic health. Analysts suggest this cardiovascular benefit could further cement $LLY's leadership position in the obesity drug market, which is shaping up to be a trillion-dollar opportunity.
Bristol Myers Squibb ($BMY) continues to see strong uptake for its CAR-T therapy Breyanzi, which has topped a $1B run rate following expansion across five cancers with a new FDA approval. The drug's rapid growth is helping offset generic competition pressures facing the company's older products. Meanwhile, Moderna ($MRNA) closed at $54.26, moving 2.69% higher in recent trading.

Healthcare M&A Activity

Bullish

Organon Takeover Bid Range

$10-12Bbinding offer submitted
OGNMRK
Organon ($OGN) shares surged following reports that Sun Pharmaceutical Industries submitted a binding offer to acquire the company in a deal valued at approximately $10 billion to $12 billion. The market reaction was immediate following reports that emerged around April 10-13, 2026. Organon is identified as one of the potential takeover targets with strong price momentum. The acquisition would represent a significant consolidation move in the women's health and biosimilars segments where Organon operates.

Biopharma Pipeline Updates

Neutral
REGNMRK
The generalized myasthenia gravis treatment pipeline continues to advance with several promising late-stage candidates in development. Key programs include IMVT-1402 from Immunovant/Roivant Sciences, Descartes-08 from Cartesian Therapeutics, and Remibrutinib and FABHALTA (Iptacopan) from Novartis. Additional candidates include Gefurulimab from Alexion AstraZeneca Rare Disease, MAVENCLAD (Cladribine) from Merck KGaA, Telitacicept from RemeGen, and Pozelimab plus Cemdisiran from Regeneron Pharmaceuticals ($REGN). These emerging therapies are advancing through clinical development and signal a potential new treatment era for the rare autoimmune disease.

Analyst Actions & Valuations

Neutral

AbbVie Price Target

$232from $233

Medtronic Price Target

$120from $125

Amgen Share Price

$350.73+18%

Amgen vs S&P 500 Outperformance

14.8%+6-month period
ABBVMDTAMGN
Wall Street analysts made several adjustments to healthcare names ahead of quarterly earnings. Evercore ISI lowered its price target on AbbVie ($ABBV) to $232 from $233 while reiterating an Outperform rating, updating estimates in a Q1 preview note. Mizuho reduced its price target on Medtronic ($MDT) to $120 from $125 but maintained an Outperform rating as the firm updated estimates ahead of Q1 results.
Amgen ($AMGN) has experienced an impressive run over the past six months, with shares beating the S&P 500 by 14.8% and now trading at $350.73, marking an 18% gain partly driven by solid quarterly results.

Managed Care & Health Services

Neutral
UNH
The managed care sector faces evolving dynamics as shifting costs and policy changes reshape the industry landscape.
UnitedHealth Group ($UNH) maintains advantages through its integrated Optum engine and earnings stability compared to peers like Elevance Health. Analysts note that $UNH's diversified care delivery model provides greater resilience as the sector navigates regulatory uncertainty and reimbursement pressures. The health insurance segment continues to balance growth initiatives with cost management amid ongoing policy debates around drug pricing and Medicare negotiations.

Looking Ahead

Neutral
JNJABT
Johnson & Johnson ($JNJ) announced it will present at the Bank of America 2026 Healthcare Conference with management participating in a Fireside Chat at 2:20 p.m. Eastern Time on Tuesday, May 12th, 2026.
Abbott Laboratories ($ABT) is among the big names on the earnings docket for the remainder of this week. Investors continue to monitor drug pipeline developments, FDA regulatory decisions, and M&A activity as key catalysts for the healthcare sector heading into the second quarter of 2026.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy